Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Depreciation & Amortization (CF) (2016 - 2025)

Coherus Oncology's Depreciation & Amortization (CF) history spans 13 years, with the latest figure at $896000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 13.26% year-over-year to $896000.0; the TTM value through Dec 2025 reached $3.9 million, down 25.63%, while the annual FY2025 figure was $3.9 million, 25.63% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $896000.0 at Coherus Oncology, down from $966000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $1.5 million in Q3 2024 and bottomed at $767000.0 in Q1 2022.
  • The 5-year median for Depreciation & Amortization (CF) is $957500.0 (2023), against an average of $1.0 million.
  • The largest annual shift saw Depreciation & Amortization (CF) skyrocketed 72.3% in 2024 before it plummeted 37.64% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $836000.0 in 2021, then grew by 25.6% to $1.0 million in 2022, then grew by 1.24% to $1.1 million in 2023, then fell by 2.82% to $1.0 million in 2024, then fell by 13.26% to $896000.0 in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Depreciation & Amortization (CF) are $896000.0 (Q4 2025), $966000.0 (Q3 2025), and $1.0 million (Q2 2025).